1. A Phase 3, Multi-Site, Randomized, Mixed-Blind, Parallel-Group Treatment Withdrawal And Re-Treatment Study Of The Efficacy And Safety Of 2 Oral Doses Of CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis. Clinical Trial Profile
2. Pfizer Inc. Oral Tasocitinib Demonstrates Statistically Significant Response by 12 Weeks in Phase 2 Study of People With Moderate to Severe Plaque Psoriasis. http://www.pfizer.com, 07 Oct 2010 Media Release
3. A Phase 2 Randomized, Multicenter, Active Comparator-Controlled Trial to Evaluate the Safety and Efficacy of Co-Administration of CP-690,550 and Mycophenolate Mofetil/Mycophenolate Sodium in De Novo Renal Allograft Recipients. Clinical Trial Profile
4. Pfizer Inc. Potential New Pfizer Medicine Reduces Transplant Rejection Rates in Animal Studies, Without Side Effects of Current Therapies. http://www.pfizer.com, 30 Oct 2003 Media Release
5. Pfizer Inc. In First Phase 3 Trial, Tasocitinib (CP-690,550), an Oral JAK Inhibitor, Administered as Monotherapy, Reduces Signs and Symptoms of Active Rheumatoid Arthritis and Improves Physical Function. http://www.pfizer.com, 08 Nov 2010 Media Release